Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Was that for me? Surely it wasn't. hence the need to use the reply button.
How do you come to the conclusion that they're selling into demand at a measured pace, which is somehow keeping support under the stock.
Nobody has any idea except management and the 3 hired firms. I don't think they are selling much, if any at all. I'm hoping they have gotten enough from the ATM already.
I think if they raised enough to make their quarter cash flow neutral, that would be enough. If a contract is imminent or will happen in the very near future, why dilute more than you need to at these prices. Stop selling, and the price would go even that much higher.
That being said, those 3 firms have done a great job peaking interest in this stock.
The king poster of old news pointing out another's post of old news. Thanks for the chuckle.
Nice volume happening today. If we could close above $1.90 that would be great. Think we will have a good close today.
June $2 and $3 options are now available for anyone interested.
Thanks for the reposting of that Spidey. Very relevant as that was the topic of conversation of late. Much appreciated.
Sorry no need to cry. Criticize all you like. Don't see many contradictory points from you on pretty much any posts I make or any for that matter with regards to this company. Copy and paste seems to be catching on with this board. Glad you think managements doing a top notch job. Hope Elbit works out for ya. At least they knew poor management when they saw it. Lmao.
I do take responsibility for my investment decisions. Nobody's fault but my own for believing management and what they have falsely stated for all these years. Even gives me more of a right to be critical of their action in the year they promised would be ours. You seem to follow Elbit board as well, so you must be a fan on management then.
Maybe you're happy having cash tied up doing jack squat for so many years. I'm sure many are not. Holding people accountable for their vast number of missteps, is not complaining, just FACTUAL. Management stinks and I'm sorry if they are buddies of yours, but they deserve to be ousted if nothing significant by year end. Period.
But to be at the same place we were 8 years ago, complaining is justified imo.
I guess you couldn't come up with anything to back up your erroneous claims...just call me names, give up the losing battle, then rehash some other old stuff. What purpose does posting old releases without any though or insight do aside from clutter up the board. Put some thought into what you post and see if it lives up to the scrutiny of others.
At least when you do that, it can create discussion of things that are actually relevant to the situation, and makes people think about possibilities with what you feel like discussing, both good and bad. Just putting a paragraph of a news release with a link to the release, is absolutely pointless as we have all read it before.
Wow. That would be totally amazing!!! Drop Charite for them, and then gift them a share of the pie. I think we now have triplets!!!
So let's say we get some sort of stockpiling contract. It would only be available to the U.S. for now, so we wouldn't be getting getting contracts from other governments until fda approval.
For arguments sake, let's say it's for 10,000 doses @ $10,000 each. That would be a $100,000,000 contract. We would have the ability to make that in several months wouldn't we? Numbers could be off on either one, but I think that could be a fair assumption.
Now with that $100,000,000, do you not think they could easily build/buy/ a gmp facility preparing for a ramp up for FUTURE contracts.
And I'm not even sure if that is the amount they can produce with their existing, already expanded facility. Or can they build more bioreactors that could boost production. The square footage of their facility was quite large, and by the looks of the pictures, the equipment seems pretty small. The size of a table maybe.
There are not contracts yet, no approvals, nada. So to do some sort of partnership with Lonza makes zero sense in every way I look at it at this time. If next month we needed to produce 500,000 doses, maybe. But that seems so extremely unlikely, it's pointless to talk about it.
You keep bringing up the same things over and over again, without providing any new or valid explanations to the points I bring up. IMO. Just the same old stale tea leaves.
Really you just write so much all over the place so you can look like there's some sort of response to my valid questions about your assumptions, but in reality, there isn't. Slowly written or otherwise.
So here's some new cans opened up from your reply.
Now we are going to abandon the research partnership with Charite, the ones who are involved with orthopaedic indications. Let's abandon Tobias Winkler and his involvement with the development of our current and products and future products.
All so we can set up some sort of a partnership with a manufacturing company to help develop our products. Abandon a world renowned facility to partner with one that may just be looking to get into the drug game. That would make tons of sense.
And I guess now, if we are going to join forces with Lonza in order to build up our production capabilities, building our own prematurely was just a complete waste of money, and even worse, time.
Again, you totally avoided the question of why would Pluristem want to give Lonza the ability to grow MSC'S, the only type they can grow so you say. Why would Lonza want to if Pluristem owns all the rights to grow in 3d bioreactor? Again to grow them for Pluristem.
From day 1, management has boasted about their "in house" manufacturing abilities. Partnering with them just blows that whole statement up. To lease space from Lonza, could possibly be a small possibility. A very far out possibility IMO
But I think if they get a contract that is beyond their production capabilities, there would have an extremely large $ value associated with it. They could just buy their own GMP facility, just like Lonza just did.
So the possibilities you throw out there are riddled with holes and go against what management has wanted to do the whole time, control their own manufacturing abilities. Makes zero sense to me.
So let me get this straight. Pluristem's 3d bioreactor, can only grow MSC's like the claim you made, confirmed by an apparent email you sent IR a while ago.
So Pluristem is now going to do a deal with Lonza so THEY can grow MSC's on an "industrial" scale.
Since all of our drugs, clinical, preclinical, proof of concepts, use MSC's, we are now going to do a deal with Lonza, so THEY can grow these cells for our competitors? Any company that is using MSC's would be a competitor wouldn't they.
Or are we going to do a deal with them to use our Bioreactor to grow cells for us? LMAO.
Please clarify your position in the tea leaf mystery you feel the need to bring up over and over. I anxiously await your response to enlighten me, the one that has no clue what I'm talking about.
Sorry but I believe Lonza already can produce on an Industrial scale. That's what I meant by commercial. They have won the manufacturing race for the biotech industry, IMO.
A key point in the article you want to keep posting.
“Most of today’s cell therapy production platforms are based on 2D technologies, such as cell factories or cell stacks,”
Key word being MOST. What are the others and what are they using. I believe Lonza already has the ability to manufacture commercial quantities of cells, so no partnership needed. And besides, you claim only MSC's can be grown in our bioreactor. Can't have it both ways can you?
Sent an email to IR asking if any type of cells can be grown in our bioreactor. No response as of yet. Have yet to have a single question I have ever asked, answered or even an acknowledgment that an email was received. I've emailed both Karine and Efrat on many occasions, but I guess they too, don't want to deal with shareholder questions, just like the twins. But if I do get a response, I will let you know. Not holdimg my breath.
You just proved the point. A 5 page blurb, 2 of which are the safe harbor section. Just a rehash of a couple of things already covered in previous news releases, and the "increased interest from Asia".
Wow thanks management. With all the different irons in the fire, you would think they could have come up with something a little better don't you think? Communication with shareholders is pretty much nonexistent to say the least. This lack of communication just fuels the flames for anyone who believes management is well over their head like I do.
Cmon...they're GREAT places to release news. Where have I heard that one a hundred times. Vast majority of them are useless IMO.
You made me feel like the government in your previous post. Throwing lots of cash at the wall with my endeavour in options, but nothing's stuck so far. Up quite a bit on the March ones, but doesn't cover the previous two sets...yet.
My guts telling me next week or the following one for something of significance. But then again, I've been saying that for 7 years! It will be right one of these weeks/months/years/soon to be decades.
Hey Blue. Respectfully, I'm not too sure on your assessment of Cleveland Biolabs. Sure if something was to happen, they would be using their product, as it is available. In what quantities, I have no idea. But that is why PLX should be a top priority for them as well. To have another product on their shelves would be an incredible asset to have.
But something seems fishy about their study on ARS. It was discussed in depth a little while ago. Just something about it didn't seem right. And being involved with Russia just seems to add to my doubt.
They are sitting at a $35 million market cap. So I would think the street doesn't believe anything is imminent. But if you got some coin there as well, your odds of one of them getting a stockpiling contract is greater.
There are others in this space, and we are not alone. The need to have some product(s) available is obviously an understatement. I do believe that we are one of the top, if not THE top, product candidates to fill this void. Filgrastim, with all its blood transfusions and other measures that go along with it, seems unlikely to be desired if mass casualties were to happen.
But you sure hit the nail on the head. Competition is abound everywhere in the pharmaceutical industry. Many with incredibly deep pockets to back small biotechs to diversify their drugs and drug candidates. The longer the delays, the more likely others will be first to market.
This ARS pivotal trial is so important both financially and to give credence to their products. Hit a home run with this one, and so many offers will come in for their others, even a backseat driving, Joe Schmo like me could make a deal.
On the brighter side with Cleveland Biolabs, they WERE given substantial contracts for the development of ARS by the DOD. The cash they received was used up sometime in 2016. If anyone follows CBLI, please feel free to correct me if I'm wrong. I've just done some brief research on them the last time this conversation came about.
They are sitting at a market cap of $35 mil. And that was after a run up on rumours of stockpiling contract that has yet to come about. So I'm not too concerned about CBLI at least for now.
Allo, they may not have the product that we are hoping/thinking we have. But they are a competitor nonetheless, and should definitely be included in any conversation regarding competition in the ARS market.
One day we will eventually hear about the much anticipated interim results from HCT trial. Maybe then we will get confirmation with some real facts and numbers regarding the recovery of the three blood lineages Allo often refers to. The safety aspect of it in humans will also be a big asset to the pursuit of ARS approval, providing it's positive obviously.
Holy. Yes in preparation would work as that clearly states they haven't started the actual trial yet. But preparations would mean trial design and contract negotiations. Don't think it would involve the actual procurement of NHP's yet. Would be putting the cart before the horse.
Now if it was management running the show entirely, they would have gotten them back in May. Ok that was a little offside.
I do not agree in the least. If you got a call and was told someone was in an accident and are undergoing surgery, you would think they're in surgery right now hands down. You wouldn't think they are prepping the tools, or cleaning the OR, but they are cut open and getting fixed. But enough on that topic. Here's a real one.
Why is there a delay in getting this thing started? It is obvious that both sides want to get this started asap. My only concern is the government is playing hardball, knowing Pluristem desperately needs this to continue operations into the future.
Could their stumble in not getting a contract for the first two phases be hindering the negotiations. They let the government pay for the study costs without getting any direct development compensation. Is the government asking for a similar deal?
I have no clue how much doing an NHP trial would cost. I don't think either of the first two phases' costs would come even close to the lower contracts of $50 million that competing companies received. Even a 150 NHP wouldn't cost that much would it? But again I have no idea.
And I believe the holdup for closing the Sosei deal rests on them having a substantial increase in cash in their coffers. So much is depending on this contract.
All I know is that it's been over 4 months since dosing trial was competed. That seems like an eternity considering the potential threats this world is facing, and the obvious need for a potential cure for ARS.
I believe we will be able to tell the caliber of our management by the terms of this contract. A $40+ million deal would be a win. A paid trial would be a fail. Still great either way as we need to get this started. But a true test of our managements skills.
All IMO of course.
No way. Undergoing means it is already going on. About to undergo would work as would preparing for like you stated, but what was said, does not. In the very least it is extremely misleading. Especially with the monumental implications it would have if it were to already been started.
When looking at the benefits of Orphan Drug Designation yesterday I came across an articles which had the following paragraph.
There is an even greater potential for profit when drugs have multiple orphan disease indications or if they can later go on to be used for more widespread non-orphan indications; for example, Gleevec® from Novartis Oncology resulted in sales of $2.4 billion in 2010. In addition, a number orphan drugs are biologics, meaning they are less likely to have generic equivalents, which extends the value to sponsors even after patent expiration.
https://criteriuminc.com/wordpress/index.php/orphan-drug-development-why-they-are-so-important/
And from that article just posted
Aberman said this approval could fast-track the cell product use for other indications relating to damaged hematological systems, including failed bone-marrow transplants, blood disorders because of prolonged chemotherapy or radiation treatment, and genetic blood disorders or related cancers. Collectively, this would mean improved treatment for millions of people.
If they could just get this contract completed and get this phase 3 NHP trial started, other indications could come on line soon after upon having good results and getting it approved.
13000 in the U.S. alone have this type of blood disorder. It's was great to see quotes from Prof. Or, who actually administered the treatment. Sure all three died eventually, but to go from deathbed to discharged and having an extra 9 months (I believe) to live is amazing. And who knows, regular administration of PLX may have prolonged their life substantially more.
Cmon get this contract signed so we can get the Plx show on the road.
"PLX-R18 is now undergoing second- and third-stage trials in the US with the support of the US National Institute of Health, the department of defense and the Food and Drug Administration"
Did I miss the start of the phase 3 trials? It's undergoing already? This article was written with the cooperation with Pluristem as it states at the end. So you would think if it WAS written in cooperation with them, they would see it before it gets published, to make sure what is said is accurate.
So it is either an outright lie, or it has started, in which case they epically failed to disclose. If that cooperation statement wasn't there I could care less as it's just someone making an error that always seems to occur. But it is there and that's what irks me. A lot of great stuff in there, but that point should never have been put in there.
Well written TC. I know I come across as a basher, but I do believe in this product or I wouldn't be here. I do distrust management for obvious reasons. I like to try to keep them honest, so to speak, and balance out the cheerleading that does happen here too often. The champagne gets popped a little prematurely.
I don't think it will be a matter of if, but when this thing takes off. Unfortunately the when is the crucial part when trading options. Hence when they miss their promised deadlines, if infuriates me as it costs me money. And thanks for the support as well Jack. Much appreciated.
Do you really need some reasons why Blue and I think they're over their heads? I will start a list. Feel free to add as there's so many. At least for anyone without their special beer goggles on that works for management and not the ladies.
- Failed UH deal
- Failed Chinese deal
- Almost 2 years since green light for Japanese trial-hasn't started. Should call it slow track
- over a year delay on closing Sosei deal
- hired a co-ceo as one couldn't cut it
- 3, now 4 orphan drug designations with the first three still doing jack
- Plurisphere
- 2 year delay in development to build manufacturing facilities
- idle manufacturing plant for the most part
- 2 million share bonus...duh didn't see anything wrong with voting for them. Thanks board buddies
- I could write a novel on broken promises/missed milestones but if you need I can fire off another 20 lines in an instant. But I'll spare you unless you ask like you did for this.
- zero partnerships for any of their products aside from ARS. But how long have they said that they would get partners
- others developing ARS treatments got $50 million to over $300 million in development costs. We got trials paid for.
- no CC's
- pocket mans great pocket line
- And the real kicker. A share price that has been around the same as it was 9 years ago. And that would have been much lower if it weren't for this recent run up. Way to go management.
These are things that just popped into my head. I'm sure if I went through previous milestones from years past, there would be a plethora of others.
Wow a gain of 3.45% today. Not far off from the average that study saw with orphan drug designation at 3.37%.
Do small startup companies gift themselves almost 4% of the company while shareholders sit in limbo for the last 7 years? Board buddies and themselves didn't even do comparisons to other small startups, only the following quarter after the big bonuses. And then to put in a cost cutting contingency plan into their report. You would think that $5 million bonus (when it happened) would have been better served elsewhere.
So I will take every opportunity to criticize the twins where I see fit. I strongly believe this company would be much farther ahead if they had some real talent running the ship, with actual experience in this field. . Why is it we need 2 CEO's??? Did they ever give any real explanation as to why this was done? Nope!!!
If they had been given options like other startups get, would have been a little easier to swallow. If they were given them AFTER some significant news where shareholders saw some significant gains, no problem. Like Blue says, this is a public company. Where shareholders like all of us (technically not me...yet) should be considered in their actions.
Accountability is lost in this corporate world we live in. Since my minute voice in this grand scheme of things will do nothing to change or shape anything. But if they don't deliver this year like promised, maybe it will be the start of something. To get new management in place to get this great technology that they stumbled upon, known, and doing what it was meant to do, save lives. And in doing so, make investors a boat load of money.
Is it common sense to be wrong on pretty much every guess you have made on this company. Or is that genius.
Exactly my point. Just a guess as to the reason for what is happening. An IMO, would suit that post fine.
As you don't like what we have to say, I'm certainly no fan of people who put blinders on and can't debate a subject that is really important to a companies success. Just because it's negative, doesn't mean it's not an important discussion. I always ask for someone to "show me the light", and give intelligent rebuttals. Instead all I get is a little line taken from my posts, and any relevant points are just ignored. Sigh. Thanks again coach.
Again, keep up the good work Blue. I understand you no problem.
Funny I was searching importance of orphan drug status for a company, and came across a study based on companies announcing such a thing. It found an average increase of 3.36%. Pretty much where we started, although we are dropping a little now. Be curious where we end up at the end of the day.
https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-017-0665-6?site=ojrd.biomedcentral.com
And what are you basing that statement on? Pure guess? Or is there any smidge of factual evidence you have to back up that claim.
This is some very good news. One that will not only increase our odds of getting a contract for the pivotal trial, but for a stockpiling contract. When that big news happen is the million dollar question. Wish we would see some June contracts come out. I like to stay as far out as I can.
Glad to see your return Blue. Well said.
Nice to see a company actually get a deal. Potential for milestone payments of up to $300+ mil. We get a postponed "binding" term sheet where the company will pay $11 mil to set up the company. No upfront fees. And they can't even get that done. Don't understand why there's such a thing as binding when a company can just back away.
How anyone can sit here and be so happy about Pluristem astonishes me every time I see it. Let's take almost a fourth of the company as a gift, slap shareholders in the chops, and postpone "our" year until 2018. It's like a cult. Kind of reminds me of rural America. Patience of Job, I guess.
I remember everyone saying they'll raise hell if nothing happens in 2017, now it's fine.
We all know the risks and know the potential. Doesn't mean we are not allowed to criticize where we see fit. Many have been around for many years, and complaining about what this company promises and misses is very justified. If you don't like to hear legitimate complaints, there's an ignore button somewhere.
Lmao. Morning rituals of the Pluristem longs. My wife's up at 5, so that's my time to check the TASE and see how it's doing. I wait until she's in the shower so I don't have to hear about it. Sometimes she comes back in while the showers running and catches me. The pitiful head shake is what I get.
We will get there. We have to. Show the significant others we're not nuts.
I hear you Melon, and thanks. Most of everything is over my head. Logic is what I base most of what I write on. May be off base sometimes, but the lack of rebuttals I get seem to be confirmation that I am on the right track, somewhat at least. Whether people want to believe it or not, I think management has dropped the ball on many things.
I do however, believe in the product and the product alone. Just went through multiple posts on gaffs I believe happened with regards to manufacturing, but the product pushes on. If it were not for ARS potential in the very near term, I think we would be in serious trouble.
Just want that government contract to come through now, so the initiation of the pivitol trial can start asap. Don't need a 2 year delay in starting something like the Japanese fiasco. If they could do the pivitol study all at once instead of 2 cohorts, all the better. We will be about a year away from serious contracts provided results are good. Maybe less. Seeing some positive interim results from HCT would be great to see right about now. Would take us for a bigger run than we have had, considering the parallels with ARS IMO
Cmon show is this run is for a reason. Every day I wake up, check the phone in excitement, and then disappointment. Looking for that excitement to stay all day long. A little taste of it for the past few weeks, but I'm waiting for the big one. GLTA longs
Those are familiar phrases, but that is about the time that he first left Pluristem for Lonza. Process is the product probably stuck in his head.
What is your opinion Melon, on the 3d biorector only being able to grow MSC's. I personally don't know what the difference would be between growing one type of cell or another. Seems like it would be possible to do imo. Also, couldn't any cell be tweaked by changing ph levels etc. Why would it not do the same in a 2d environment. Any help would be greatly appreciated. Well beyond me, but would like to know from someone with some knowledge in this area.
So why did they bring about the idea of Plurisphere? Was that for any cell type? Not sure I believe you when you say it can only grow MSCs. Would love for you to show me anything stating that. I don't ever recall anything like that, so is that just your opinion or is there any factual basis to that claim.